ANTWERP, Belgium, February 2, 2026.
Agomab Therapeutics NV (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need, today announced the launch of its initial public offering of 12,500,000 American Depositary Shares (“ADSs”), each ADS representing one of its common shares, no nominal value per share, pursuant to a registration statement filed with the Securities and Exchange Commission (“SEC”). Agomab expects to grant the underwriters in the offering a 30-day option to purchase up to an additional 1,875,000 ADSs at the initial public offering price, less underwriting discounts and commissions. The estimated initial public offering price is between $15.00 and $17.00 per ADS. Agomab has applied to list its ADSs on the Nasdaq Global Market under the symbol “AGMB”.

Antwerp, Belgium, January 8, 2026
Agomab Therapeutics NV (‘Agomab’), a clinical-stage biopharmaceutical company focused on fibrosis, today announced positive interim results of the Phase 1 study of AGMB-447 in healthy participants. AGMB-447 is an inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1) intended for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

Antwerp, Belgium, November 17, 2025   Agomab Therapeutics NV (‘Agomab’) today announced positive data from 103 participants completing 12 weeks of treatment in the STENOVA Phase 2a clinical trial for ontunisertib (AGMB-129), an investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (TGFβ RI or ALK5) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD). The company also provided a safety update on the ongoing open-label extension (OLE) study with ontunisertib.